STMH (Stem Holdings) EBITDA Margin %: -19.73% (As of Sep. 2023)

What is Stem Holdings EBITDA Margin %?

Stem Holdings STMH -99.00% 12 EBITDA Margin % is -19.73% as of Sep. 2023. GuruFocus rates STMH with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Stem Holdings's EBITDA for the three months ended in Sep. 2023 was $2.33 Mil. Stem Holdings's Revenue for the three months ended in Sep. 2023 was $-11.78 Mil. Therefore, Stem Holdings's EBITDA margin for the quarter that ended in Sep. 2023 was -19.73%.

Stem Holdings (OTCPK:STMH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Stem Holdings EBITDA Margin % Related Terms

Stem Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Stem Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Holdings EBITDA Margin % Chart

Stem Holdings Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBITDA Margin %

Get a 7-Day Free Trial

-1,026.76

-47.90

-29.05

0.00

Stem Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															-21.28	-55.68	-55.42	-12.82	-19.73

STMH vs NXEN, VFRM, ENDPQ: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Stem Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stem Holdings EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Stem Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Stem Holdings's EBITDA Margin % falls into.

Save Embed

12GF Score

Stem Holdings Inc STMH

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Stem Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Stem Holdings's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-3.932	/	0
	=	%

Stem Holdings's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	2.325	/	-11.783
	=	-19.73 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -19.73% mean?

Stem Holdings (STMH) has a EBITDA Margin % of -19.73% as of Sep. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stem Holdings and its competitors.

Is Stem Holdings' EBITDA Margin % too high?

Stem Holdings' current EBITDA Margin % is -19.73%. Overall, Stem Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Stem Holdings' EBITDA Margin % compare to NXEN and VFRM?

Stem Holdings' EBITDA Margin % of -19.73% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stem Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Holdings's current EBITDA Margin % is -19.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Stem Holdings stock overvalued right now?

Stem Holdings (STMH) has a current EBITDA Margin % of -19.73%. The current EBITDA Margin % is -19.73%. Stem Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Stem Holdings (STMH), the current EBITDA Margin % is -19.73% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stem Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NXEN VFRM ENDPQ PCYN HCANF CSUI AKAN SXTC BSPK CPHI ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Address 2201 NW Corporate Boulevard, Suite 205, Boca Raton, FL, USA, 33431

Website https://www.stemholdings.com

Stem Holdings Inc is involved in a cannabis business. The company is engaged in the manufacture, possession, sale, distribution, and branding of cannabis and its related products. Its brand includes TJ's Gardens; Yerba Buena; Cannavore; Dose-ology and Travis X James.

12GF Score

Get the complete analysis for STMH

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View STMH Analysis

See EBITDA Margin % data for all stocks →